Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.76 |
| ▸ | DDX5 | P17844 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | HBB | P68871 | 2/20 | 0.73 |
| ▸ | CASP1 | P29466 | 1/20 | 0.73 |
| ▸ | CASP7 | P55210 | 1/20 | 0.73 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | GLA | P06280 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | STAT6 | P42226 | 1/20 | 0.73 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | GMNN | O75496 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27764694 | 0.88 | TOP1 (0.86) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3513607 | 0.88 | TOP1 (0.86) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3138027 | 0.87 | TOP1 (0.82) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29429769 | 0.86 | TOP1 (1.00) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18296599 | 0.86 | TOP1 (1.00) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9563404 | 0.86 | TOP1 (1.00) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30255916 | 0.86 | TOP1 (1.00) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18296600 | 0.86 | TOP1 (1.00) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29473358 | 0.86 | TOP1 (1.00) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13931437 | 0.86 | TOP1 (1.00) | TOP1DDX5MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305148-A1 | DI-ESTER PRODRUGS OF CAMPTOTHECIN, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-02 | — | — | US | disclosed |
| US-7700612-B2 | Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications | ABRAXIS BIOSCIENCE, LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-20070161668-A1 | Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications | AMERICAN BIOSCIENCE, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| WO-2005062991-A2 | TEN AND 20-DI-ESTERIFICATION DERIVATIVES OF CAMPTOTHECINS AND METHODS TO TREAT CANCERS | AMERICAN BIOSCIENCE, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005062985-A2 | DI-ESTER PRODRUGS OF CAMPTOTHECIN, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL APPLICATIONS | AMERICAN BIOSCIENCE, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1200443-B1 | AROMATIC ESTERS OF CAMPTOTHECINS AND METHODS TO TREAT CANCERS | STEHLIN FOUNDATION FOR CANCER (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6407239-B1 | TOPOISOMERASE INHIBITORS | THE STEHLIN FOUNDATION FOR CANCER RESEARCH | 2002-06-18 | — | — | US | disclosed |
| EP-1200443-A1 | AROMATIC ESTERS OF CAMPTOTHECINS AND METHODS TO TREAT CANCERS | THE STEHLIN FOUNDATION FOR CANCER RESEARCH (US) | 2002-05-02 | — | — | EP | disclosed |
| US-20020049324-A1 | Aromatic esters of camptothecins and methods to treat cancers | GIOVANELLA, BEPPINO | 2002-04-25 | — | — | US | disclosed |
| US-6228855-B1 | TOPOISOMERASE INHIBITORS; ANTITUMOR AGENTS | THE STEHLIN FOUNDATION FOR CANCER RESEARCH | 2001-05-08 | — | — | US | disclosed |
| WO-2001009139-A1 | AROMATIC ESTERS OF CAMPTOTHECINS AND METHODS TO TREAT CANCERS | THE STEHLIN FOUNDATION FOR CANCER RESEARCH (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161668-A1 | Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications | DCTD, PAICS, PDE11A | TOP1 41/4885DDX5 3219/4885MEN1 1369/4885 |
| US-20020049324-A1 | Aromatic esters of camptothecins and methods to treat cancers | VHL, BRCA1, TP53 | TOP1 7/4885DDX5 1114/4885MEN1 539/4885 |
| US-20100305148-A1 | DI-ESTER PRODRUGS OF CAMPTOTHECIN, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL APPLICATIONS | DCTD, PAICS, PDE11A | TOP1 41/4885DDX5 3219/4885MEN1 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.